Exploration of modified progression-free survival as a novel surrogate endpoint for overall survival in immuno-oncology trials

BACKGROUND: Progression-free survival (PFS) exhibits suboptimal performance as the surrogate endpoint for overall survival (OS) in trials studying immune checkpoint inhibitors (ICIs). Here we propose a novel surrogate endpoint, modified PFS (mPFS), which omits the events of disease progression (but...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Zi-Xian, Wu, Hao-Xiang, Xie, Li, Lin, Wu-Hao, Liang, Fei, Li, Jin, Yang, Zhi-Min, Xu, Rui-Hua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8021890/
https://www.ncbi.nlm.nih.gov/pubmed/33795385
http://dx.doi.org/10.1136/jitc-2020-002114

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8021890/
https://www.ncbi.nlm.nih.gov/pubmed/33795385
http://dx.doi.org/10.1136/jitc-2020-002114

Ejemplares similares